Suven Life Sciences, a Hyderabad-based life sciences company, today announced that it has bagged a Rs 20 crore custom synthesis order for a phase-III drug.According to a an official release issued today, Suven has initiated more than 300 projects under the contract research and manufacturing services (CRAMS) business model. Out of these, 52 are active at various stages of clinical development by the innovators - 26 projects are in phase I, 21 are in phase II and 5 are in phase III."Recently, one of the phase II projects moved into phase III resulting in an order of Rs 20 crore for an intermediate, which has to be supplied within the next six months. With this, Suven's total pending order position is at $10 million," the release added.
